JP2008531580A
(en)
*
|
2000-12-08 |
2008-08-14 |
スリーエム イノベイティブ プロパティズ カンパニー |
Compositions and methods for targeted delivery of immune response modifiers
|
WO2003037860A2
(en)
|
2001-10-30 |
2003-05-08 |
Conforma Therapeutics Corporation |
Purine analogs having hsp90-inhibiting activity
|
US7321033B2
(en)
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
WO2003051882A1
(en)
*
|
2001-12-18 |
2003-06-26 |
Cv Therapeutics, Inc. |
A2a adenosine receptor antagonists
|
GB0215293D0
(en)
|
2002-07-03 |
2002-08-14 |
Rega Foundation |
Viral inhibitors
|
DK1545597T3
(en)
|
2002-08-15 |
2011-01-31 |
3M Innovative Properties Co |
Immune Stimulating Compositions and Methods for Stimulating an Immune Response
|
EP1550662B1
(en)
|
2002-09-27 |
2012-07-04 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound and use thereof
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
EP1601365A4
(en)
|
2003-03-04 |
2009-11-11 |
3M Innovative Properties Co |
Prophylactic treatment of uv-induced epidermal neoplasia
|
US8426457B2
(en)
|
2003-03-13 |
2013-04-23 |
Medicis Pharmaceutical Corporation |
Methods of improving skin quality
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US7923560B2
(en)
|
2003-04-10 |
2011-04-12 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
BRPI0412902A
(en)
|
2003-08-12 |
2006-09-26 |
3M Innovative Properties Co |
oxime-substituted imidazo-containing compounds
|
CA2536136C
(en)
|
2003-08-27 |
2012-10-30 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
US7576068B2
(en)
|
2003-09-05 |
2009-08-18 |
Anadys Pharmaceuticals, Inc. |
Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
|
AU2004270201A1
(en)
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for CD5+ B cell lymphoma
|
WO2005028434A2
(en)
|
2003-09-18 |
2005-03-31 |
Conforma Therapeutics Corporation |
Novel heterocyclic compounds as hsp90-inhibitors
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
CA2540541C
(en)
|
2003-10-03 |
2012-03-27 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
US8598192B2
(en)
|
2003-11-14 |
2013-12-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazoquinolines
|
WO2005048933A2
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
AU2004293078B2
(en)
|
2003-11-25 |
2012-01-19 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
JP2007513165A
(en)
|
2003-12-02 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Concomitant drugs containing IRM compounds and methods of treatment
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
NZ548074A
(en)
|
2003-12-22 |
2010-08-27 |
Gerhard Puerstinger |
Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
|
EP1701955A1
(en)
|
2003-12-29 |
2006-09-20 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
WO2005066169A2
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
CA2559863A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
JPWO2005092892A1
(en)
*
|
2004-03-26 |
2008-02-14 |
大日本住友製薬株式会社 |
8-Oxoadenine compounds
|
US8012964B2
(en)
|
2004-03-26 |
2011-09-06 |
Dainippon Sumitomo Pharma Co., Ltd. |
9-substituted 8-oxoadenine compound
|
WO2005123080A2
(en)
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006009832A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US20090208456A1
(en)
*
|
2004-07-27 |
2009-08-20 |
Gilead Sciences, Inc. |
Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
WO2006066080A1
(en)
|
2004-12-17 |
2006-06-22 |
Anadys Pharmaceuticals, Inc. |
3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
|
PT1841765E
(en)
|
2004-12-21 |
2009-05-14 |
Gilead Sciences Inc |
Imidazo[4,5-c]pyridine compound and method of antiviral treatment
|
US7943609B2
(en)
|
2004-12-30 |
2011-05-17 |
3M Innovative Proprerties Company |
Chiral fused [1,2]imidazo[4,5-C] ring compounds
|
ES2392648T3
(en)
|
2004-12-30 |
2012-12-12 |
3M Innovative Properties Company |
Substituted chiral compounds containing a condensed 1,2-imidazo-4,5-c core
|
US9248127B2
(en)
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
EP1846405A2
(en)
|
2005-02-11 |
2007-10-24 |
3M Innovative Properties Company |
Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
|
AU2006232377A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
CA2602590A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
BRPI0611435A2
(en)
|
2005-05-04 |
2010-09-08 |
Pfizer Ltd |
2-starch-6-amino-8-oxopurine derivatives, pharmaceutical compositions, use and process for preparing same
|
WO2007011777A2
(en)
|
2005-07-18 |
2007-01-25 |
Novartis Ag |
Small animal model for hcv replication
|
JP2009504803A
(en)
*
|
2005-08-22 |
2009-02-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
TLR agonist
|
JP4584335B2
(en)
*
|
2005-09-02 |
2010-11-17 |
ファイザー・インク |
Hydroxy-substituted 1H-imidazopyridine and method
|
TW200801003A
(en)
*
|
2005-09-16 |
2008-01-01 |
Astrazeneca Ab |
Novel compounds
|
US20090099216A1
(en)
*
|
2005-09-22 |
2009-04-16 |
Astrazeneca Aktiebolag A Corporation Of Sweden |
Novel adenine compound
|
US20080269240A1
(en)
*
|
2005-09-22 |
2008-10-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel Adenine Compound
|
US20090105212A1
(en)
|
2005-09-22 |
2009-04-23 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
TW200745114A
(en)
*
|
2005-09-22 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
WO2007034881A1
(en)
*
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel adenine compound
|
JPWO2007034817A1
(en)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
New adenine compounds
|
KR20080090400A
(en)
|
2005-11-21 |
2008-10-08 |
애나디스 파마슈티칼스, 인코포레이티드 |
Process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
|
JPWO2007060918A1
(en)
|
2005-11-24 |
2009-05-07 |
大日本住友製薬株式会社 |
Novel memory CTL induction enhancer
|
WO2007109813A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
EP2700638A1
(en)
*
|
2006-05-31 |
2014-02-26 |
The Regents Of the University of California |
Purine analogs
|
CA2655904C
(en)
|
2006-06-22 |
2014-11-18 |
Anadys Pharmaceuticals, Inc. |
Prodrugs of 5-amino-3-(3'-deoxy-.beta.-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
|
US8138172B2
(en)
*
|
2006-07-05 |
2012-03-20 |
Astrazeneca Ab |
8-oxoadenine derivatives acting as modulators of TLR7
|
MX2009000235A
(en)
|
2006-07-07 |
2009-01-23 |
Gilead Sciences Inc |
Novel pyridazine compound and use thereof.
|
WO2008008432A2
(en)
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
|
ATE499940T1
(en)
|
2006-07-18 |
2011-03-15 |
Anadys Pharmaceuticals Inc |
CARBONATE AND CARBAMAT PRODRUGS OF THIAZOLO Δ4,5-DÜ-PYRIMIDINES
|
EP2086582B1
(en)
|
2006-10-12 |
2012-11-14 |
GlaxoSmithKline Biologicals s.a. |
Vaccine comprising an oil in water emulsion adjuvant
|
TW200831105A
(en)
*
|
2006-12-14 |
2008-08-01 |
Astrazeneca Ab |
Novel compounds
|
PL2125007T3
(en)
|
2007-02-07 |
2014-07-31 |
Univ California |
Conjugates of synthetic tlr agonists and uses therefor
|
PT2132209E
(en)
|
2007-03-19 |
2014-04-15 |
Astrazeneca Ab |
9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
|
JP5329444B2
(en)
*
|
2007-03-19 |
2013-10-30 |
アストラゼネカ・アクチエボラーグ |
9-Substituted-8-oxo-adenine compounds as TOLL-like receptor (TLR7) modulators
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
TW200902018A
(en)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
TW200908994A
(en)
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
PL2155743T3
(en)
*
|
2007-05-08 |
2013-01-31 |
Astrazeneca Ab |
Imidazoquinolines with immuno-modulating properties
|
UA99466C2
(en)
|
2007-07-06 |
2012-08-27 |
Гилиад Сайенсиз, Инк. |
Crystalline pyridazine compound
|
PE20091236A1
(en)
|
2007-11-22 |
2009-09-16 |
Astrazeneca Ab |
PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
|
PE20091156A1
(en)
|
2007-12-17 |
2009-09-03 |
Astrazeneca Ab |
SALTS OF (3 - {[[3- (6-AMINO-2-BUTOXY-8-OXO-7,8-DIHIDRO-9H-PURIN-9-IL) PROPYL] (3-MORFOLIN-4-ILPROPIL) AMINO] METHYL} PHENYL) METHYL ACETATE
|
SI2222710T1
(en)
|
2007-12-24 |
2016-11-30 |
Id Biomedical Corporation Of Quebec |
Recombinant rsv antigens
|
KR20100125245A
(en)
|
2008-01-17 |
2010-11-30 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
Method for producing adenine compound
|
JPWO2009091031A1
(en)
*
|
2008-01-17 |
2011-05-26 |
大日本住友製薬株式会社 |
Method for producing adenine compound
|
WO2009099650A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Carson Dennis A |
Treatment of bladder diseases with a tlr7 activator
|
RS54306B1
(en)
|
2008-04-16 |
2016-02-29 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
WO2010033074A1
(en)
*
|
2008-09-18 |
2010-03-25 |
Astrazeneca Ab |
Use of a tlr7 agonist for the treatment of cancer
|
JP5731978B2
(en)
*
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
Heterocyclic kinase inhibitor
|
CN102325790A
(en)
|
2008-12-03 |
2012-01-18 |
西马生物医学计划公司 |
Use of phenol-soluble modulins for vaccine development
|
UY32306A
(en)
|
2008-12-09 |
2010-07-30 |
Gilead Sciences Inc |
DERIVATIVES OF PTERIDINONE AND PYRIMIDINODIAZEPINONE AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE THE TOLL TYPE RECEIVERS, METHODS AND USES
|
WO2010088924A1
(en)
|
2009-02-06 |
2010-08-12 |
Telormedix Sa |
Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
|
EP2607365A1
(en)
*
|
2009-02-11 |
2013-06-26 |
The Regents of The University of California |
Toll-like receptor modulators and treatment of diseases
|
GB0908772D0
(en)
*
|
2009-05-21 |
2009-07-01 |
Astrazeneca Ab |
New salts 756
|
WO2010133885A1
(en)
|
2009-05-21 |
2010-11-25 |
Astrazeneca Ab |
Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
|
WO2010149743A2
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine
|
CA2766211A1
(en)
|
2009-06-24 |
2010-12-29 |
Glaxosmithkline Biologicals S.A. |
Recombinant rsv antigens
|
EP3988115A3
(en)
|
2009-07-15 |
2022-08-17 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
US8507507B2
(en)
|
2009-10-22 |
2013-08-13 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
EP2507237A1
(en)
*
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
US20110150836A1
(en)
*
|
2009-12-22 |
2011-06-23 |
Gilead Sciences, Inc. |
Methods of treating hbv and hcv infection
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
WO2011134668A1
(en)
|
2010-04-30 |
2011-11-03 |
Telormedix Sa |
Phospholipid drug analogs
|
US9050319B2
(en)
|
2010-04-30 |
2015-06-09 |
Telormedix, Sa |
Phospholipid drug analogs
|
GB201009273D0
(en)
|
2010-06-03 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel vaccine
|
EP2651937B8
(en)
|
2010-12-16 |
2016-07-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
|
WO2012080730A1
(en)
|
2010-12-17 |
2012-06-21 |
Astrazeneca Ab |
Purine derivatives
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
GB201120000D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2013139744A1
(en)
|
2012-03-18 |
2013-09-26 |
Glaxosmithkline Biologicals S.A. |
Method of vaccination against human papillomavirus
|
AU2013261267B2
(en)
|
2012-05-18 |
2017-06-29 |
Sumitomo Pharma Co., Ltd. |
Carboxylic acid compounds
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
JP2015525794A
(en)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Method for eliciting an immune response against RSV and Bordetella pertussis in infants
|
EP3608332B1
(en)
|
2013-03-15 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Vaccine against human rhinovirus
|
BE1022008B1
(en)
|
2013-08-05 |
2016-02-03 |
Glaxosmithkline Biologicals S.A. |
COMBINED IMMUNOGENIC COMPOSITIONS
|
EP3556353A3
(en)
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
TWI806081B
(en)
|
2014-07-11 |
2023-06-21 |
美商基利科學股份有限公司 |
Modulators of toll-like receptors for the treatment of hiv
|
PT3194401T
(en)
|
2014-09-16 |
2020-12-23 |
Gilead Sciences Inc |
Solid forms of a toll-like receptor modulator
|
CA2977493C
(en)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
JP6764930B2
(en)
|
2015-09-29 |
2020-10-07 |
大日本住友製薬株式会社 |
Use of adenine conjugate compound and its vaccine adjuvant
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
MX2019006349A
(en)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof.
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
EP3603619A4
(en)
|
2017-03-29 |
2020-12-09 |
Sumitomo Dainippon Pharma Co., Ltd. |
Vaccine adjuvant formulation
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
AU2018391899A1
(en)
|
2017-12-21 |
2020-07-02 |
Sumitomo Pharma Co., Ltd. |
Combination drug including TLR7 agonist
|
WO2019209811A1
(en)
|
2018-04-24 |
2019-10-31 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (tlr7) agonists
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
WO2020022272A1
(en)
|
2018-07-23 |
2020-01-30 |
公益財団法人ヒューマンサイエンス振興財団 |
Composition containing influenza vaccine
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
WO2021026803A1
(en)
|
2019-08-14 |
2021-02-18 |
Novartis Ag |
Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
|
JP2023512208A
(en)
|
2020-01-27 |
2023-03-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists
|
JP2023512227A
(en)
|
2020-01-27 |
2023-03-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists
|
CN115135655A
(en)
|
2020-01-27 |
2022-09-30 |
百时美施贵宝公司 |
1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7(TLR7) agonists
|
WO2021154668A1
(en)
|
2020-01-27 |
2021-08-05 |
Bristol-Myers Squibb Company |
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
|
JP2023512230A
(en)
|
2020-01-27 |
2023-03-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
C3-substituted 1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists
|
EP4097105A1
(en)
|
2020-01-27 |
2022-12-07 |
Bristol-Myers Squibb Company |
1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
|
KR20220132589A
(en)
|
2020-01-27 |
2022-09-30 |
브리스톨-마이어스 스큅 컴퍼니 |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists
|
US20230140430A1
(en)
|
2020-01-27 |
2023-05-04 |
Bristol-Myers Squibb Company |
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
|
CN115151548A
(en)
|
2020-01-27 |
2022-10-04 |
百时美施贵宝公司 |
1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists
|
IL303334A
(en)
|
2020-12-02 |
2023-07-01 |
Glaxosmithkline Biologicals Sa |
Donor strand complemented fimh
|
US20220396830A1
(en)
*
|
2021-05-13 |
2022-12-15 |
Promega Corporation |
Bioluminescent detection of dna synthesis
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|